EP2968193A4 - Methods and devices for preparation of lipid nanoparticles - Google Patents

Methods and devices for preparation of lipid nanoparticles

Info

Publication number: EP2968193A4
Authority: EP; European Patent Office
Prior art keywords: preparation; methods; devices; lipid nanoparticles; nanoparticles
Prior art date: 2013-03-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP14769279.2A

Other languages

German (de)

French (fr)

Other versions

EP2968193B1 (en

EP2968193A1 (en

Inventor

De-Min Zhu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cureport Inc

CUREPORT Inc

Original Assignee

Cureport Inc

CUREPORT Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2016-06-01

2014-03-14 Application filed by Cureport Inc, CUREPORT Inc filed Critical Cureport Inc

2016-01-20 Publication of EP2968193A1 publication Critical patent/EP2968193A1/en

2016-06-01 Publication of EP2968193A4 publication Critical patent/EP2968193A4/en

2021-09-01 Application granted granted Critical

2021-09-01 Publication of EP2968193B1 publication Critical patent/EP2968193B1/en

Status Active legal-status Critical Current

2034-03-14 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Dispersion Chemistry (AREA)
Nanotechnology (AREA)
Optics & Photonics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP14769279.2A 2013-03-15 2014-03-14 Methods and devices for preparation of lipid nanoparticles Active EP2968193B1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361791054P	2013-03-15	2013-03-15
US14/209,187 US9693958B2 (en)	2013-03-15	2014-03-13	Methods and devices for preparation of lipid nanoparticles
PCT/US2014/027064 WO2014152200A1 (en)	2013-03-15	2014-03-14	Methods and devices for preparation of lipid nanoparticles

Publications (3)

Publication Number	Publication Date
EP2968193A1 EP2968193A1 (en)	2016-01-20
EP2968193A4 true EP2968193A4 (en)	2016-06-01
EP2968193B1 EP2968193B1 (en)	2021-09-01

Family

ID=51581146

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP14769279.2A Active EP2968193B1 (en)	2013-03-15	2014-03-14	Methods and devices for preparation of lipid nanoparticles

Country Status (9)

Country	Link
US (2)	US9693958B2 (en)
EP (1)	EP2968193B1 (en)
JP (1)	JP6450742B2 (en)
KR (1)	KR20150127580A (en)
CN (1)	CN105188685B (en)
AU (1)	AU2014240013B2 (en)
CA (1)	CA2898047A1 (en)
MX (1)	MX2015011072A (en)
WO (1)	WO2014152200A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9693958B2 (en) *	2013-03-15	2017-07-04	Cureport, Inc.	Methods and devices for preparation of lipid nanoparticles
PT3766916T (en)	2014-06-25	2022-11-28	Acuitas Therapeutics Inc	Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016141167A1 (en) *	2015-03-03	2016-09-09	Cureport, Inc.	Combination liposomal pharmaceutical formulations
JP2018507227A (en) *	2015-03-03	2018-03-15	キュアポートインコーポレイテッド	Liposome drug formulation with two drugs
CN107708672A (en) *	2015-06-15	2018-02-16	华盛顿大学	For extending the multiple medicine lipidic nanoparticles composition and correlation technique of the levels of drugs in blood and lymphoid tissue
HRP20220872T1 (en)	2015-10-22	2022-12-23	Modernatx, Inc.	Respiratory virus vaccines
FI3368507T3 (en)	2015-10-28	2023-03-21	Acuitas Therapeutics Inc	Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2017253107B2 (en)	2016-04-19	2023-07-20	Massachusetts Institute Of Technology	CPF1 complexes with reduced indel activity
US20210155911A1 (en)	2016-04-19	2021-05-27	The Broad Institute, Inc.	Novel crispr enzymes and systems
WO2017189308A1 (en)	2016-04-19	2017-11-02	The Broad Institute Inc.	Novel crispr enzymes and systems
US11352647B2 (en)	2016-08-17	2022-06-07	The Broad Institute, Inc.	Crispr enzymes and systems
CN110312799A (en)	2016-08-17	2019-10-08	博德研究所	Novel C RISPR enzyme and system
US11357856B2 (en)	2017-04-13	2022-06-14	Acuitas Therapeutics, Inc.	Lipids for delivery of active agents
WO2018191750A2 (en)	2017-04-14	2018-10-18	The Broad Institute Inc.	Novel delivery of large payloads
US11786607B2 (en)	2017-06-15	2023-10-17	Modernatx, Inc.	RNA formulations
CA3069019A1 (en) *	2017-07-10	2019-01-17	Immunovaccine Technologies Inc.	Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
WO2019023873A1 (en) *	2017-07-31	2019-02-07	江苏竞诺择生物医药科技有限公司	Nano-lipid microparticle composition and pharmaceutical composition for treating hematopoietic system proliferative diseases
EP3668834B1 (en)	2017-08-17	2024-10-02	Acuitas Therapeutics, Inc.	Lipids for use in lipid nanoparticle formulations
JP7275111B2 (en)	2017-08-31	2023-05-17	モデルナティエックスインコーポレイテッド	Method for producing lipid nanoparticles
WO2019135816A2 (en)	2017-10-23	2019-07-11	The Broad Institute, Inc.	Novel nucleic acid modifiers
US12221720B2 (en)	2017-11-13	2025-02-11	The Broad Institute, Inc.	Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
US12018080B2 (en)	2017-11-13	2024-06-25	The Broad Institute, Inc.	Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
JP7344300B2 (en)	2018-09-18	2023-09-13	ブイエヌブイニューコインク．	ARC-based capsids and their uses
CA3113651A1 (en)	2018-09-20	2020-03-26	Modernatx, Inc.	Preparation of lipid nanoparticles and methods of administration thereof
EP3852911B1 (en) *	2018-09-21	2025-01-22	Acuitas Therapeutics, Inc.	Systems and methods for manufacturing lipid nanoparticles and liposomes
IL284535B2 (en)	2019-01-11	2025-03-01	Acuitas Therapeutics Inc	Lipids for lipid nanoparticle delivery of active agents
US12215382B2 (en)	2019-03-01	2025-02-04	The General Hospital Corporation	Liver protective MARC variants and uses thereof
WO2020186213A1 (en)	2019-03-14	2020-09-17	The Broad Institute, Inc.	Novel nucleic acid modifiers
WO2020191102A1 (en)	2019-03-18	2020-09-24	The Broad Institute, Inc.	Type vii crispr proteins and systems
WO2020236972A2 (en)	2019-05-20	2020-11-26	The Broad Institute, Inc.	Non-class i multi-component nucleic acid targeting systems
AU2020348872A1 (en)	2019-09-20	2022-04-14	Massachusetts Institute Of Technology	Compositions and methods for delivering cargo to a target cell
EP3915673A1 (en) *	2020-05-25	2021-12-01	Leon-Nanodrugs GmbH	Method for checking the operability of a system for the production of nanoparticles by selective precipitation from supersaturated solutions
EP3915544A1 (en) *	2020-05-25	2021-12-01	Leon-Nanodrugs GmbH	Method for producing a liposome dispersion
AU2021308681A1 (en)	2020-07-16	2023-03-09	Acuitas Therapeutics, Inc.	Cationic lipids for use in lipid nanoparticles
DE102020214601A1 (en) *	2020-11-19	2022-05-19	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein	Process and device for the production of a liquid containing liposomes and the liquid produced
WO2022225368A1 (en) *	2021-04-22	2022-10-27	(주)인벤티지랩	Lipid nanoparticle preparation method and preparation apparatus therefor
CN117377465A (en) *	2021-05-05	2024-01-09	莱昂纳米药物有限公司	Method for producing nanoparticle dispersions
AU2023250649A1 (en)	2022-04-04	2024-11-14	The Regents Of The University Of California	Genetic complementation compositions and methods
KR102475540B1 (en) *	2022-04-26	2022-12-08	주식회사 무진메디	Method and apparatus for manufacturing drug-loaded lipid nanoparticles
KR102474542B1 (en)	2022-06-17	2022-12-06	다온 주식회사	Solid-State Power Amplifier for Customer Premise Equipment
WO2024133600A1 (en)	2022-12-20	2024-06-27	Nanocell Therapeutics B.V.	Integrating and self-inactivating viral vectors and constructs and uses thereof
KR20240119725A (en)	2023-01-30	2024-08-06	주식회사 케이런	Microfluidic mixing device for manufacturing nanoparticles
CN116271087B (en) *	2023-02-03	2024-11-19	中山大学·深圳	Preparation method and application of polyethylene glycol modified lipid nano-disk with adjustable particle size

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009120247A2 (en) *	2007-12-27	2009-10-01	The Ohio State University Research Foundation	Lipid nanoparticle compositions and methods of making and using the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1920008A (en)		1933-07-25		of wilmington
US5030453A (en)	1983-03-24	1991-07-09	The Liposome Company, Inc.	Stable plurilamellar vesicles
US4895452A (en) *	1988-03-03	1990-01-23	Micro-Pak, Inc.	Method and apparatus for producing lipid vesicles
US5032457A (en) *	1988-03-03	1991-07-16	Micro Vesicular Systems, Inc.	Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
IL91664A (en)	1988-09-28	1993-05-13	Yissum Res Dev Co	Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5145256A (en) *	1990-04-30	1992-09-08	Environmental Equipment Corporation	Apparatus for treating effluents
ATE138803T1 (en)	1990-07-31	1996-06-15	Liposome Co Inc	ACCUMULATION OF AMINO ACIDS AND PEPTIDES IN LIPOSOMES
US5800833A (en)	1995-02-27	1998-09-01	University Of British Columbia	Method for loading lipid vesicles
US5891467A (en)	1997-01-31	1999-04-06	Depotech Corporation	Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
BR0012624B1 (en)	1999-07-15	2011-08-09		methods for preparing lipid-wrapped therapeutic agents.
US6680068B2 (en)	2000-07-06	2004-01-20	The General Hospital Corporation	Drug delivery formulations and targeting
SI1345597T1 (en) *	2000-12-27	2007-12-31	Ares Trading Sa	Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
EP1399189A1 (en)	2001-06-11	2004-03-24	Universite De Montreal	Compositions and methods for enhancing nucleic acid transfer into cells
CA2456977C (en)	2001-08-16	2011-06-07	The Trustees Of The University Of Pennsylvania	Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies
EP2302389B1 (en) *	2002-05-09	2018-01-24	The University of Chicago	Device and method for pressure-driven plug transport and reaction
DK1519714T3 (en) *	2002-06-28	2011-01-31	Protiva Biotherapeutics Inc	Method and apparatus for preparing liposomes
WO2004029213A2 (en)	2002-09-28	2004-04-08	Massachusetts Institute Of Technology	Compositions and methods for delivery of short interfering rna and short hairpin rna
US20040208921A1 (en)	2003-01-14	2004-10-21	Ho Rodney J. Y.	Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues
BRPI0415480B1 (en)	2003-10-16	2019-09-17	Nestec S.A.	NUTRITIONAL COMPOSITION AGAINST CHEMOTHERAPY OR RADIOTHERAPY SIDE EFFECTS
JP2006153677A (en) *	2004-11-30	2006-06-15	Dainippon Screen Mfg Co Ltd	Differential pressure type flowmeter, flow rate control device, and substrate treatment apparatus
JP2008534508A (en)	2005-03-22	2008-08-28	メドスターヘルスインコーポレイテッド	Delivery system and method for diagnosing and treating cardiovascular disease
EP1904219A4 (en) *	2005-07-15	2011-07-27	Map Pharmaceuticals Inc	Method of particle formation
US8304849B2 (en) *	2005-12-29	2012-11-06	Intel Corporation	Apparatus to send biological fluids through a printed wire board
WO2008005045A2 (en) *	2005-12-30	2008-01-10	Dermazone Solutions, Inc.	Nanolipidic particles
US20080171078A1 (en) *	2007-01-12	2008-07-17	Mark Gray	Uniformly sized liposomes
US7985058B2 (en) *	2007-01-12	2011-07-26	Mark Gray	Method and apparatus for making uniformly sized particles
US8067390B2 (en)	2007-03-02	2011-11-29	The Board Of Regents Of The University Of Texas System	Therapeutic targeting of interleukins using siRNA in neutral liposomes
FR2916974B1 (en)	2007-06-11	2010-11-26	Univ Angers	PROCESS FOR THE PREPARATION OF LIPID NANOPARTICLES
BRPI0821895A2 (en) *	2008-04-04	2014-10-07	Robert Shorr	PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF A DISEASE, A CONDITION AND SYMPTOMS OF THE SAME IN HOT BLOOD ANIMALS, INCLUDING HUMAN BEINGS, METHOD FOR PREPARATION OF THE PHARMACEUTICAL COMPOSITION, METHOD DIAGNOSIS
JP2010069476A (en) *	2008-08-20	2010-04-02	Yunifiido Engineering:Kk	Liquid mixing apparatus
JP2010075914A (en) *	2008-08-25	2010-04-08	National Institute Of Advanced Industrial Science & Technology	High temperature-high pressure micro mixing device
WO2010078045A2 (en) *	2008-12-17	2010-07-08	Oncothyreon, Inc.	Method of making small liposomes
NO329468B1 (en) *	2009-01-07	2010-10-25	Framo Eng As	Apparatus for providing a controllable pressure reduction.
BRPI1008869A2 (en)	2009-02-04	2016-03-15	Brigham & Womens Hospital	nanoparticle, compound, pharmaceutical composition, method for treating cancer or metastasis, and prolonged release method of a platinum compound
US20100221347A1 (en) *	2009-02-18	2010-09-02	Ritman Erik L	Enhancing solute transport within a tissue scaffold
JP2012519577A (en)	2009-03-06	2012-08-30	エールフエルト・ミクロテヒニク・ベー・テー・エス・ゲー・エム・ベー・ハー	Coaxial small static mixer and its use
FR2948035B1 (en)	2009-07-20	2015-04-24	Centre Nat Rech Scient	PROCESS FOR MANUFACTURING CAPSULES, CAPSULES THUS OBTAINED AND USE OF SAID CAPSULES
JP5558883B2 (en) *	2010-03-30	2014-07-23	畑村洋太郎	Mixing device, gradation mixture and method for producing mixture
EP2558074B1 (en) *	2010-04-08	2018-06-06	The Trustees of Princeton University	Preparation of lipid nanoparticles
US9693958B2 (en)	2013-03-15	2017-07-04	Cureport, Inc.	Methods and devices for preparation of lipid nanoparticles

2014
- 2014-03-13 US US14/209,187 patent/US9693958B2/en active Active
- 2014-03-14 KR KR1020157021385A patent/KR20150127580A/en not_active Withdrawn
- 2014-03-14 WO PCT/US2014/027064 patent/WO2014152200A1/en active Application Filing
- 2014-03-14 JP JP2016502326A patent/JP6450742B2/en active Active
- 2014-03-14 CA CA2898047A patent/CA2898047A1/en not_active Abandoned
- 2014-03-14 MX MX2015011072A patent/MX2015011072A/en unknown
- 2014-03-14 EP EP14769279.2A patent/EP2968193B1/en active Active
- 2014-03-14 CN CN201480012955.7A patent/CN105188685B/en active Active
- 2014-03-14 AU AU2014240013A patent/AU2014240013B2/en active Active
2017
- 2017-06-15 US US15/623,983 patent/US11497715B2/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009120247A2 (en) *	2007-12-27	2009-10-01	The Ohio State University Research Foundation	Lipid nanoparticle compositions and methods of making and using the same

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"METHODS IN ENZYMOLOGY", vol. 465, 1 January 2009, ACADEMIC PRESS, US, ISSN: 0076-6879, article BO YU ET AL: "Microfluidic Methods for Production of Liposomes", pages: 129 - 141, XP055266923, DOI: 10.1016/S0076-6879(09)65007-2 *
ANDREAS JAHN ET AL: "Microfluidic Directed Formation of Liposomes of Controlled Size", LANGMUIR, vol. 23, no. 11, 1 May 2007 (2007-05-01), pages 6289 - 6293, XP055036503, ISSN: 0743-7463, DOI: 10.1021/la070051a *
BISWAJIT MUKHERJEE: "Doxorubicin-loaded phosphatidylethanolamine-conjugated nanoliposomes: in vitro characterization and their accumulation in liver, kidneys, and lungs in rats", INTERNATIONAL JOURNAL OF NANOMEDICINE, 1 October 2010 (2010-10-01), pages 811 - 823, XP055065701, DOI: 10.2147/IJN.S13031 *
IGOR V. ZHIGALTSEV ET AL: "Bottom-Up Design and Synthesis of Limit Size Lipid Nanoparticle Systems with Aqueous and Triglyceride Cores Using Millisecond Microfluidic Mixing", LANGMUIR, vol. 28, no. 7, 21 February 2012 (2012-02-21), pages 3633 - 3640, XP055150435, ISSN: 0743-7463, DOI: 10.1021/la204833h *
NATHAN M BELLIVEAU ET AL: "Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA", NUCLEIC ACIDS AND MOLECULAR BIOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 1, no. 8, 1 August 2012 (2012-08-01), pages e37 - 1, XP002715253, ISSN: 0933-1891, [retrieved on 20120814], DOI: 10.1038/MTNA.2012.28 *
See also references of WO2014152200A1 *

Also Published As

Publication number	Publication date
JP6450742B2 (en)	2019-01-09
US20140348900A1 (en)	2014-11-27
WO2014152200A1 (en)	2014-09-25
US9693958B2 (en)	2017-07-04
EP2968193B1 (en)	2021-09-01
KR20150127580A (en)	2015-11-17
US20180000735A1 (en)	2018-01-04
AU2014240013B2 (en)	2018-07-12
EP2968193A1 (en)	2016-01-20
MX2015011072A (en)	2015-10-22
US11497715B2 (en)	2022-11-15
JP2016517423A (en)	2016-06-16
AU2014240013A1 (en)	2015-08-13
CA2898047A1 (en)	2014-09-25
CN105188685A (en)	2015-12-23
CN105188685B (en)	2021-06-15
WO2014152200A4 (en)	2014-11-13

Publication	Publication Date	Title
EP2968193A4 (en)	2016-06-01	Methods and devices for preparation of lipid nanoparticles
GB2535360B (en)	2017-04-12	Methods of preparing polyhemiaminals and polyhexahydrotriazines
HK1220473A1 (en)	2017-05-05	Anti-alpha-synuclein antibodies and methods of use --
GB2518286B (en)	2020-01-22	Security device and method of manufacture
GB2517079B (en)	2020-06-17	Security devices and methods of manufacture
HK1217968A1 (en)	2017-01-27	Methods and compositions for modification of hla hla
EP2997770A4 (en)	2016-11-16	Methods of discovery and measurements for small cellsinofdm/ofdmasystems
SG11201504442YA (en)	2015-07-30	Semiconductor device and method of making semiconductor device
EP3081530A4 (en)	2017-06-21	Anthracite-based method for preparation of graphene and graphene oxide
GB201301790D0 (en)	2013-03-20	Security devices and methods of manufacture thereof
IL241878B (en)	2021-09-30	Macrolides and methods of their preparation and use
GB201401761D0 (en)	2014-03-19	Security devices and methods of manufacture thereof
GB2510381B (en)	2015-11-04	Security devices and methods of manufacture thereof
SG11201505841XA (en)	2015-09-29	Photonic device structure and method of manufacture
HK1221416A1 (en)	2017-06-02	Formulations of oxabicycloheptanes and oxabicycloheptenes
GB2511560B (en)	2018-11-14	Improved Packaging and Method of Forming Packaging
HK1225612A1 (en)	2017-09-15	Anti-ly6e antibodies and methods of use
EP2995905A4 (en)	2017-04-05	X-ray device and manufacturing method of structure
ZA201602198B (en)	2020-11-25	Preparation of hydroxy-benzylbenzene derivatives
EP3049066A4 (en)	2017-05-17	Compositions and methods for the manufacture of lipid nanoparticles
HK1224307A1 (en)	2017-08-18	Protoxin-ii variants and methods of use -ii
GB2511559B (en)	2018-11-14	Improved Packaging and Method of Forming Packaging
EP3021665A4 (en)	2017-03-22	Methods and devices for sustained release of substances
EP2971241A4 (en)	2016-11-23	Anisotropic conductor and method of fabrication thereof
SG11201507389RA (en)	2015-10-29	Integration of hydro-dechlorination and hydro-regeneration

Legal Events

Date	Code	Title	Description
2015-12-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-01-20	17P	Request for examination filed	Effective date: 20150731
2016-01-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-01-20	AX	Request for extension of the european patent	Extension state: BA ME
2016-02-10	RIN1	Information on inventor provided before grant (corrected)	Inventor name: ZHU, DE-MIN
2016-06-01	A4	Supplementary search report drawn up and despatched	Effective date: 20160503
2016-06-01	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/51 20060101AFI20160426BHEP
2016-06-22	DAX	Request for extension of the european patent (deleted)
2018-02-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-03-28	17Q	First examination report despatched	Effective date: 20180226
2020-08-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-03-24	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2021-03-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2021-04-14	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20210305BHEP Ipc: A61P 31/12 20060101ALI20210305BHEP Ipc: A61P 31/10 20060101ALI20210305BHEP Ipc: A61P 25/04 20060101ALI20210305BHEP Ipc: A61K 31/704 20060101ALI20210305BHEP Ipc: A61K 9/127 20060101ALI20210305BHEP Ipc: A61K 9/51 20060101AFI20210305BHEP
2021-04-21	INTG	Intention to grant announced	Effective date: 20210325
2021-07-26	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2021-07-30	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2021-07-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2021-09-01	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-09-01	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2021-09-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1425464 Country of ref document: AT Kind code of ref document: T Effective date: 20210915
2021-09-23	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602014079850 Country of ref document: DE
2021-09-29	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2021-12-27	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2022-01-05	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20210901
2022-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211201 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211201 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901
2022-02-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1425464 Country of ref document: AT Kind code of ref document: T Effective date: 20210901
2022-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211202
2022-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220101 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220103 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901
2022-06-02	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602014079850 Country of ref document: DE
2022-07-08	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2022-07-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901
2022-08-10	26N	No opposition filed	Effective date: 20220602
2022-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901
2022-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901
2022-12-07	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20220331
2023-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220314 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220314
2023-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220331
2023-06-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230515
2023-07-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20230402 Year of fee payment: 10
2024-03-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140314
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901
2024-07-08	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20240529 Year of fee payment: 11
2024-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210901
2024-10-10	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DE Payment date: 20240717 Year of fee payment: 11
2024-10-16	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: FR Payment date: 20240726 Year of fee payment: 11
2024-10-21	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20240722 Year of fee payment: 11